Department of Endocrinology, Seth GS Medical College, Mumbai, India.
Endocr Pract. 2012 Sep-Oct;18(5):694-9. doi: 10.4158/EP12050.OR.
To establish pediatric reference ranges for plasma fractionated free metanephrines by enzyme immunoassay (EIA) and to evaluate its performance in the diagnosis of catecholamine-secreting tumors in the pediatric population.
Normotensive children and children with suspected catecholamine-secreting tumors underwent measurement of plasma fractionated metanephrines by EIA to establish pediatric reference ranges. Children with suspected pheochromocytoma or paraganglioma also underwent magnetic resonance imaging or computed tomography from the neck to the pelvis and were followed up for a minimum of 1 year. Diagnosis of pheochromocytoma/paraganglioma was confirmed by histologic examination. Pheochromocytoma/paraganglioma was excluded in children who had a histologic diagnosis other than pheochromocytoma/paraganglioma and in those who had no imaging evidence of tumor and no progression on follow-up.
Plasma fractionated metanephrines were measured in 78 normotensive children (age range, 1.5-17 years) and in 38 children with suspected catecholamine-secreting tumors. Of the 38 children (age range, 6-17 years) with suspected pheochromocytoma/paraganglioma, 17 had a histopathologically proven catecholamine-secreting tumor. The newly derived pediatric upper reference limit for metanephrine (128 pg/mL) was higher than in adults (90 pg/mL), whereas the pediatric upper reference limit for normetanephrine (149 pg/mL) was lower than in adults (180 pg/mL). The manufacturer's reference range for plasma fractionated metanephrines yielded a sensitivity of 100% and a specificity of 85.7%. Use of newly established pediatric reference ranges increased the specificity to 95.2% without altering the sensitivity (100%).
Plasma fractionated metanephrines by EIA provide an accurate test with good sensitivity and specificity for the diagnosis of pheochromocytoma and paraganglioma in children. Use of pediatric reference ranges improves accuracy of the test.
建立酶免疫分析法(EIA)检测血浆游离甲氧基肾上腺素的儿科参考范围,并评估其在儿科人群中诊断儿茶酚胺分泌肿瘤的性能。
对血压正常的儿童和疑似儿茶酚胺分泌肿瘤的儿童进行 EIA 检测血浆游离甲氧基肾上腺素,以建立儿科参考范围。疑似嗜铬细胞瘤或副神经节瘤的儿童还进行了颈部至骨盆的磁共振成像或计算机断层扫描,并进行了至少 1 年的随访。通过组织学检查确认嗜铬细胞瘤/副神经节瘤的诊断。在组织学诊断为非嗜铬细胞瘤/副神经节瘤的儿童和无肿瘤影像学证据且随访无进展的儿童中排除嗜铬细胞瘤/副神经节瘤。
在 78 名血压正常的儿童(年龄范围为 1.5-17 岁)和 38 名疑似儿茶酚胺分泌肿瘤的儿童中测量了血浆游离甲氧基肾上腺素。在 38 名(年龄范围为 6-17 岁)疑似嗜铬细胞瘤/副神经节瘤的儿童中,17 名有组织病理学证实的儿茶酚胺分泌肿瘤。新获得的儿童甲氧基肾上腺素(128pg/ml)上限参考值高于成人(90pg/ml),而儿童去甲肾上腺素(149pg/ml)上限参考值低于成人(180pg/ml)。该制造商的血浆游离甲氧基肾上腺素参考范围的敏感性为 100%,特异性为 85.7%。使用新建立的儿科参考范围可将特异性提高至 95.2%,而不改变敏感性(100%)。
EIA 法检测血浆游离甲氧基肾上腺素为儿童嗜铬细胞瘤和副神经节瘤的诊断提供了一种准确性高、敏感性和特异性好的检测方法。使用儿科参考范围可提高检测的准确性。